Tim Rolph is Chief Scientific Officer and co-founder of Akero Therapeutics, a biotechnology company focused on metabolic diseases. Tim formerly was Chief Scientific Officer of Pfizer’s Cardiovascular & Metabolic Disease Research Unit. During his leadership, Steglatro™ (ertuglifozin) was discovered and developed in partnership with Merck, and recently launched as a fixed-dose combination with Januvia™ (steglujan), the leading oral medication for diabetes.Tim’s tenure at Pfizer spanned more than 22 years. He led their human anti-infective research at Sandwich (UK), directing the team that discovered the prototype CCR5 antagonist, Maraviroc, launched as a novel antiretroviral for HIV (Celzentry™). He then became Head of Research at Pfizer’s laboratory in Sandwich, and more recently at Groton in the U.S. Prior to Pfizer, Tim worked in Glaxo’s veterinary R&D group, initially studying the modulation of growth for food production, then moving into anti-parasitic research for veterinary applications.With a BSc in Biochemistry from University of London, Tim undertook graduate studies at Wolfson College, University of Oxford, being awarded a D.Phil from the Faculty of Clinical Medicine. His pre-and post-doctoral training was at the Nuffield Institute for Medical Research studying the metabolic adaptations of skeletal & cardiac muscle during development.